MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nervgen Pharma Corp (OP:NGENF)

5.840 UNCHANGED
Last Price Updated: 3:59 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 5.840
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 5.840
Today's Range 5.840 - 5.840
52wk Range 1.500 - 6.100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
From NervGen Pharma Corp.
Via GlobeNewswire

Performance

YTD
-0.7%
-0.7%
1 Month
N/A
N/A
3 Month
+39.0%
+39.0%
6 Month
+110.8%
+110.8%
1 Year
+205.8%
+205.8%

More News

Read More
News headline image
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma Begins Trading on Nasdaq Today
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Investor Forum Agenda Announced for March 13th
From Virtual Investor Conferences
Via GlobeNewswire
Non-Opioid Revolution: Beacons of Hope in Opioid Crisis and a $50 Million Spin-Off
Via AB Newswire
News headline image
Life Science Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Science Investor Forum Agenda Announced for June 22nd
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
NervGen Pharma Announces Leadership Transition
Via Newsfile
News headline image
Has The Controversy Around Falsified Alzheimer's Research Impacted The Path To Finding The Cure? ↗
Via Benzinga
News headline image
NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University
From NervGen Pharma Corp.
Via Business Wire
News headline image
Encode Ideas, L.P. Announces the Initiation of Research Coverage on NervGen Pharma Corp.
Via Newsfile
News headline image
NervGen Engages Vorticom Inc. to Provide Media Relations Services
Via Newsfile
News headline image
NervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine & Rehabilitation
From NervGen Pharma Corp.
Via Business Wire
News headline image
NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer's Disease Models
Via Newsfile
News headline image
NervGen Pharma Reports First Quarter 2021 Results
Via Newsfile
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021 ↗
Via Benzinga
News headline image
NervGen Pharma Announces Closing of Overnight Marketed Equity Offering
Via Newsfile
News headline image
NervGen Pharma Grants Stock Options
Via Newsfile
News headline image
NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291
Via Newsfile
News headline image
NervGen Pharma Announces Pricing of Overnight Marketed Equity Offering
Via Newsfile
News headline image
NervGen Pharma Corp. Announces Overnight Marketed Equity Offering
Via Newsfile
News headline image
NervGen Pharma Grants Stock Options
Via Newsfile

Frequently Asked Questions

Is Nervgen Pharma Corp publicly traded?
Yes, Nervgen Pharma Corp is publicly traded.
What exchange does Nervgen Pharma Corp trade on?
Nervgen Pharma Corp trades on the OTC Traded
What is the ticker symbol for Nervgen Pharma Corp?
The ticker symbol for Nervgen Pharma Corp is NGENF on the OTC Traded
What is the current price of Nervgen Pharma Corp?
The current price of Nervgen Pharma Corp is 5.840
When was Nervgen Pharma Corp last traded?
The last trade of Nervgen Pharma Corp was at 01/07/26 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story